This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies | MicrobiomeTrials
← Back to trials NCT06904066
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies Recruiting PHASE1 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2026-10-29Est. Completion: 2029-04-30
Enrollment target: 86 participantsLocations National Institutes of Health Clinical Center, Bethesda, Maryland, United States Other microbiome trials you might be interested in Relapsed Acute Myeloid Leukemia Refractory Acute Myeloid Leukemia B-cell Acute Lymphoblastic Leukemia Pediatric Cancer Pediatric ALL, Relapsed Pediatric ALL Pediatric ALL, B Cell Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Pediatric AML R/R AML R/R B-cell ALL
The goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescen…
Multiple Locations Est. completion Apr 30, 2030
Phase 3
Recruiting
Intrahepatic Cholangiocarcinoma (Icc)
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety o…
Guangzhou, China Est. completion Jan 2030
DOCK8 Deficiency
Background:
-DOCK8 deficiency is a genetic disorder that affects the immune system and can lead to severe recurrent inf…
Bethesda, United States Est. completion Oct 31, 2026